Biosyent Inc. (CVE:RX) Director Douglas Robert Larson sold 1,500 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of C$9.20, for a total value of C$13,800.00.

Douglas Robert Larson also recently made the following trade(s):

  • On Friday, September 15th, Douglas Robert Larson sold 200 shares of Biosyent stock. The shares were sold at an average price of C$9.25, for a total value of C$1,850.00.
  • On Wednesday, June 21st, Douglas Robert Larson sold 1,000 shares of Biosyent stock. The shares were sold at an average price of C$8.10, for a total value of C$8,100.00.
  • On Monday, June 19th, Douglas Robert Larson sold 100 shares of Biosyent stock. The stock was sold at an average price of C$8.05, for a total value of C$805.00.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: Biosyent Inc. (RX) Director Sells 1,500 Shares of Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/15/insider-selling-biosyent-inc-rx-director-sells-1500-shares-of-stock.html.

About Biosyent

BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.

Insider Buying and Selling by Quarter for Biosyent (CVE:RX)

Receive News & Ratings for Biosyent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.